Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study

Marion C Dickson, Alexandra Walker, Clive Grattan, Hayley Perry, Nicola Williams, Nirav Ratia, Odile Dewit, Sophie Gisbert, Martin Metz, Marcus Maurer, Marion C Dickson, Alexandra Walker, Clive Grattan, Hayley Perry, Nicola Williams, Nirav Ratia, Odile Dewit, Sophie Gisbert, Martin Metz, Marcus Maurer

Abstract

Aims: To explore the safety, tolerability, pharmacokinetics and pharmacodynamics (PD) of GSK2646264 using skin challenge models.

Methods: Healthy volunteers (HV) with a positive allergen skin prick test received GSK2646264 (0.5% or 1% ww) and placebo creams on up to 10% body surface area (BSA). Cold (ColdU) or chronic spontaneous (CSU) urticaria patients received 1% GSK2646264 or placebo on up to 10% BSA. PD assessments included weal characteristics after skin allergen challenge, critical temperature threshold (CTT) in ColdU patients and defined area urticaria activity score in CSU patients.

Results: Thirty-four patients were randomised (17 HV, 12 ColdU, 5 CSU). Topical application of GSK2646264 and placebo was well tolerated. Systemic pharmacokinetics (AUC [0-24] h*ng/mL) was similar between HVs (Geomean 97.9 [%CV 37]) and ColdU patients (Geomean 68.2 [%CV 14; 3.5% BSA] or 167 [%CV 120; 10% BSA]). Whilst in HVs a similar reduction in skin allergen challenge weal area was observed following 3 applications of GSK2646264 and placebo, a trend towards a greater reduction was seen in ColdU with GSK2646264 compared to placebo. A clinically meaningful reduction in CTT, in ColdU patients treated with GSK2646264, was observed in 4 of 9 patients, who demonstrated either a complete inhibition of ColdU to ≤4°C (n = 2) or partial response (reduction by >4°C, n = 2). Due to the small number of CSU patients recruited, no meaningful conclusions could be drawn from the defined area urticaria activity score PD endpoint.

Conclusion: This Phase 1/1b study confirms that GSK2646264 cream applied topically penetrates the skin and some reduction in CTT was observed. (NCT02424799).

Keywords: TempTest; chronic spontaneous urticaria; cold urticaria; skin allergen challenge; spleen tyrosine kinase.

© 2021 British Pharmacological Society.

References

REFERENCES

    1. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423-432.
    1. Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we don't know. J Allergy Clin Immunol. 2017;139(6):1772-1781.
    1. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232-247.
    1. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing and management of chronic inducible urticarias - The EAACI/GA2LEN/EDF/UNEV 2016 consensus panel recommendations 2016 update and revision. Allergy. 2016;71(6):780-802.
    1. Mlynek A, Magerl M, Siebenhaar F, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol. 2010;162(1):198-200.
    1. Zuberbier T, Aberer W, Asero R. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy. 2018;73(7):1393-1414.
    1. Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria - results of a randomized, placebo controlled trial. J Allergy Clin Immunol. 2017;140(3):864-867.
    1. Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism - results of a randomized, placebo controlled trial. J Allergy Clin Immunol. 2017;140(3):870-873.
    1. Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature. 1999;402(S6760):24-30.
    1. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122(3):569-573.
    1. Chang TS, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337-342.
    1. Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcɛRI-positive cells in the skin. Theranostics. 2017;7(5):1266-1276.
    1. Saini SS, Bindsley-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75.
    1. Hide M, Francis D, Grattan C, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in Chronic Urticaria. NEJM. 1993;328(22):1599-1604.
    1. Kaplan AP, Giménez-Arnau AM. Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519-533.
    1. Serrano-Candelas E, Martinez-Aranguren R, Valero A, et al. Comparable actions of omalizumab on mast cells and basophils. Clin Exp Allergy. 2016;46(1):92-102.
    1. Liddle J, Atkinson FL, Barker MD, et al. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorg Med Chem Lett. 2011;21(20):6188-6194.
    1. Garton NS, Barker MD, Davis RP, et al. Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors. Bioorg Med Chem Lett. 2016;26(19):4606-4612.
    1. Barker MD, Liddle J, Atkinson FL, et al. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg Med Chem Lett. 2018;28(21):3458-3462.
    1. Ramirez-Molina C, Falkencrone S, Skov PS, et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. Br J Pharmacol. 2019;176(8):1135-1142.
    1. Heinzerling L, Mari A, Bergmann KC, et al. The skin prick test - European standards. Clin Transl Allergy. 2013;3(1):3.
    1. A randomised double-blind (sponsor unblinded), single and repeat ascending dose First Time in Human study in healthy subjects, cold urticaria and chronic spontaneous urticaria subjects to investigate safety, tolerability, pharmacodynamics and pharmacokinetics of topically applied GSK2646264. GlaxoSmithKline Study Protocol. 2016. (NCT02424799)
    1. van der Wal M, Bloemen M, Verhaegen P, et al. Objective color measurements: clinimetric performance of three devices on normal skin and scar tissue. J Burn Care Res. 2013;34(3):e187-e194.
    1. Alexander SPH, Kelly E, Marrion NV, et al. The Concise Guide to PHARMACOLOGY 2015/16. Br J Pharmacol. 2017;174(S1):S1-S446.
    1. Clarke AS, Rousseau E, Wang K, et al. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis. Thromb Res. 2018;170:109-118.
    1. Long AJ, Sampson E, McCarthy RW, et al. Inhibition Induces Platelet Dependent Peri-islet Hemorrhage in the Rat Pancreas. Toxicol Pathol. 2016;44(7):998-1012.
    1. Kitai M, Fukada N, Ueno T, et al. Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice. J Pharmacol Sci. 2017;134(1):29-36.
    1. Deng GM, Lie L, Bahiat FR, et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010;62(7):2086-2092.
    1. Magerl M, Pisarevskaja D, Staubach P, Martus P, Church MK, Maurer M. Critical temperature threshold measurement for cold urticaria; a randomized controlled trial of H1-antihistamine dose escalation. Br J Dermatol. 2012;166(5):1095-1099.
    1. Metz M, Scholz E, Ferran M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010;104(1):86-92.
    1. Abajian M, Curto-Barredo L, Krause K, et al. Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria. Acta Derm Venereol. 2016;96(1):56-59.
    1. Krause K, Spohr A, Zuberbier, et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68(7):921-928.
    1. Fujisawa D, Kashiwakura J, Kita H, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol. 2014;134(3):622-633.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe